Porcine factor VIII (Hyate: C®): In vitro stability, microbiological safety and effect of heparin

Haemophilia

Volumn 3, Issue 4, 1997, Pages 254-258

  Travis, S F ^a,b   Burns, N ^a   Hofmann, P ^a  

^a UMDNJ Robert Wood Johnson Medical School at Camden   (United States)

^b Children's Hosp Philadelphia S   (United States)

Author keywords

Continuous infusion; Low molecular weight (LMW) heparin; Porcine factor VIII; Stability; Sterility; Unfractionated heparin (UH)

Indexed keywords

BLOOD CLOTTING FACTOR 8 CONCENTRATE; HEPARIN;

ARTICLE; DRUG STABILITY; DRUG STERILITY; DRUG STORAGE; PRIORITY JOURNAL;

EID: 0030662072     PISSN: 13518216     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2516.1997.00114.x     Document Type: Article

References (17)

1. McMillan CW, Webster WP, Roberts HR, Blythe WB. Continuous intravenous infusion of factor VIII in classic haemophilia. Br J Haematol 1970; 18: 659-67.
2. Hathaway WE, Christian MJ, Clarke SL, Hasiba U. Comparison of continuous and intermittent factor VIII concentrate therapy in hemophilia A. Am J Hematol 1984; 17: 85-8.
3. Weinstein RE, Bona RD, Rickles FR. Continuous Infusion of monoclonal antibody-purified factor VIII. Am J Hematol 1991; 36: 211-12.
4. Schulman S, Varon D, Keller N, Gitel S, Martinowitz U. Monoclonal purified FVIII for continuous infusion: stability, microbiological safety and clinical experience. Thromb Haemost 1994; 72: 403-7.
5. Bona RD, Weinstein RE, Weisman SJ, Bartolomeo A, Rickles FR. The use of continuous infusion of factor concentrates in the treatment of hemophilia. Am J Hematol 1989; 32: 8-13.
6. Gordon EM, Mungo R, Goldsmith JC. Lingual hemorrhage in a patient with hemophilia A complicated by a high titer inhibitor. Am J Ped Hematol Oncol 1993; 15: 107-10.
7. Gordon EM, Al-Batniji F, Goldsmith JC. Continuous infusion of monoclonal antibody-purified factor VIII. Rational approach to serious hemorrhage in patients with allo/autoantibodies to factor VIII. Am J Hematol 1994; 45: 142-5.
8. Gordon EM, Month S, Goldsmith JC. Immune tolerance induction by continuous infusion of monoclonal antibody-purified (MOAB) factor VIII in children. Blood 1993; 82: 62a.
9. Martinowitz U, Schulman S. Continuous infusion of coagulation products. Int J Pediatr Hematol Oncol 1994; 1: 471-8.
10. Gordon EM. Management of factor VIII inhibitors. Int J Pediatr Hematol Oncol 1994; 1: 529-34.
11. Martinowitz U, Schulman S, Gitel S, Horozowski H, Heim M, Varon D. Adjusted dose continuous infusion of factor VIII in patients with haemophilia A. Br J Haematol 1992; 82: 729-34.
12. Schulman S, Gitel S, Martinowitz U. The stability of factor VIII concentrates after reconstitution. Am J Hematol 1994; 45: 217-23.
13. Bona RD, Riberio M, Klatsky AU, Panek S, Magnifico M, Rickles FR. Continuous infusion of porcine factor VIII for the treatment of patients with factor VIII inhibitors. Sem Hematol 1993; 30 (Suppl. 1): 32-5.
14. Rubinger M, Schwetz N, Khoo K, Israels SJ, Johnston JB. Continuous infusion porcine factor VIII in the treatment of patients with factor viii antibodies. Blood 1994; 84 (Suppl. 1): 196a [Abstract].
15. Rubinger M, Woloschuk DMM, Schwetz N, et al. The in vitro stability of porcine factor VIII (PFVIII) (Hyate-C) and the efficacy of continuous infusion (CI) PFVIII in the treatment of patients with FVIII antibodies. Blood 1995; 86 (Suppl. 1): 886a [Abstract].
16. Nilsson IM, Kirkwood TBL, Barrowcliffe TW. In vivo recovery of factor VIII. A comparison of one-stage and two-stage assay methods. Thromb Haemost 1979; 42: 1230-9.
17. Schulman S, Bech Jensen M, Varon D, et al. Feasibility of using recombinant factor Vila in continuous infusion. Thromb Haemost 1996; 75: 432-6.